Jeune Aesthetics reports positive Phase 1 interim results for KB301 in wrinkles; plans Phase 2 for décolleté

Krystal Biotech, Inc.

94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.
75% of lateral canthal subjects had ≥1-point improvement on GAIS at two months; 67% reported improved satisfaction.
No drug-related serious adverse events; adverse events were mild-to-moderate and transient.
Phase 2 study for dynamic wrinkles of the décolleté expected to start next year; FDA meeting planned.
Improvements also seen in crepiness, hydration, and radiance in both cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.